O. Eriksson, P. Pollesello and N. E. Seris, “Inhibition of Lipid Peroxidation in Isolated Rat Liver Mitochondria by the General Anesthetic Propofol,” Biochemical Pharmacology, Vol. 44, No. 2, 1992, pp. 391-393.
 M. Tsuchiya, A. Asada, K. Maeda, Y. Ueda, E. F. Sato, M. Shindo and M. Inove, “Propofol versus Medazolam Regarding their Antioxidant Activities,” American Journal of Respiratory and Critical Care Medicine, Vol. 163, No. 1, 2001, pp. 26-31.
 N. Kanaya, B. Gable, P. A. Murray and D. S. Damron, “Propofol Increases Phosphorylation of Troponin 1 and Myosin Light Chain via Protein Kinase C Activation in Cardiomyocytes,” Anesthesiology, Vol. 98, No. 6, 2003, pp. 1363-1371.
 N. Kanaya, P. A. Murray and D. S. Damron, “Propofol Increases Ca2+ Sensitivity and Intracellular pH via Activation of Na+ -H+ Exchange in Rat Ventricular Myocytes,” Anesthesiology, Vol. 94, No. 6, 2001, pp. 1096- 1104.
 V. Ioanna, X. Theodoros, K. Eleni, P. Despoina, K. Chris, K. Athanasius and P. Lila, “Propofol: A Review of its Non-Anesthetic Effects,” European Journal of Pharmacology, Vol. 605, No. 1-3, 2009, pp. 1-8.
 T. Mammoto, M. Mukai, A. Mammoto, Y. Yamanaka, Y. Hayashi, T. Mashimo, Y. Kishi and H. Nakamura, “Intravenous Anesthetic, Propofol Inhibits Invasion of Cancer Cells,” Cancer Letter, Vol. 184, No. 2, 2002, pp. 165- 170.
 R. A. Siddiqui, M. Zerouga, M. Wu, A. Castillo, K. Harvey, G. P. Zaloga and W. Stillwell, “Anti-Cancer Properties of Propofol-Docosahexaenoate and Propofoleicosa- pentaenoate on Breast Cancer Cells,” Breast Cancer Research, Vol. 7, No. 5, 2005, pp. 645-654.
 K. A. Harvey, Z. Xu, P. Whitley, V. J. Davisson and R. A. Siddiqui, “Characterization of Anti-Cancer Properties of 2,6-Diisopropylphenoldocosahexaenoate and Analogues in Breast Cancer Cells,” Bioorganic and Medicinal Che- mistry, Vol. 18, No. 5, 2010, pp. 1866-1874.
 J. A. Monendez, S. Ropero, R. Lupu and R. Colomer, “n-6 PUFA γ-Linolenic Acid (18: 3n-6) Enhances Docetaxel (Taxotere) Cytotoxicity in Human Breast Carcinoma Expression,” Oncology Reports, Vol. 11, No. 6, 2004, pp. 1241-1252.
 M. P. Moyer, W. E. Hardman and I. Canceron, “Accelerated Action Fatty Acid (AAFA) Promotes Health of Normal Tissues and Minimizes the Toxic Side Effects of Chemotherapy,” U.S. Patent, 102907, 2002.
 S. C. Larsson, M. Kumlin, M. Ingelman-Sundberg and A. Wolk, “Dietary Longchain n-3 Fatty Acids for the Prevention of Cancer: A Review of Potential Mechanisms,” American Journal of Clinical Nutrition, Vol. 79, No. 6, 2004, pp. 935-945.
 S. Pawar and S. Chattopadhyay, “10-Undecenoic Acid an Inexpensive Source for the Synthesis of the Pheromones of Cotton Pests, Peach Tree Borer and Cherry Tree Borer,” Molecules, Vol. 2, No. 6, 1997, pp. 87-90.
 N. Bourne, J. Ireland, L. R. Stanberry and D. I. Bemstein, “Effect of Undecylenic Acid as a Topical Microbicide against Geniotal Herpes Infection in Mice and Guinea Pigs,” Antiviral Research, Vol. 40, No. 3, 1999, pp. 139- 144.
 S. D. Shafran, S. L. Sacks and F. Y. Aoki, “Topical Undecylenic Acid for Herpes Simplex Labiatus: A Multicenter, Placebo-Controlled Trial,” Journal of Infectious Diseases Infect Diseases, Vol. 176, No. 1, 1997, pp. 78-83.
 V. P. M. Rahman, S. Mukhtar, W. H. Ansari and G. Lemiere, “Synthesis, Stereochemistry and Biological Activity of Some Novel Long Chain Substituted Thiazolidin- 4-Ones and Thiazan-4-One from 10-Undecenoic Acid Hydrazide,” European Journal of Medicinal Chemistry, Vol. 40, No. 4, 2005, pp. 173-184.
 T. Yutaka, K. Masaru, R. Takao, Y. Shusaku and Y. Kenji, “Enzymatic Synthesis of Arbutin Undecylenic Acid Ester and its Inhibitory Effect on Melanin Synthesis,” Bioorganic and Medicinal Chemistry Letters, Vol. 17, No. 15, 2007, pp. 894-960.
 J. Mustafa, S. I. Khan, G. Ma, L. A. Walker and I. A. Khan, “Synthesis, Spectroscopic and Biological Studies of Novel Estolides Derived from Anti-Tumor Active 4-O-Podophyllotoximyl 12-Hydroxyl Octadec-Z-9 Eno- ate,” Lipids, Vol. 39, No. 6, 2005, pp. 659-666.
 K. J. Tronstad, K. Berge, R. K. Berge and O. Bruserud, “Modified Fatty Acids and their Possible Therapeutic Targets in Malignant Diseases,” Expert Opinion on Therapeutic Targets, Vol. 7, No. 5, 2003, pp. 663-677.